Pub Date : 1900-01-01DOI: 10.14744/ejmi.2023.76099
H. Semiz
cor-Objectives: Due to limited data in the literature, we aimed to determine the relationship between the development of chemotherapy-induced neutropenia and survival in patients with ovarian cancer who underwent frontline cytoreductive surgery and received adjuvant chemotherapy
{"title":"The Relationship Between Chemotherapy Related Neutropenia and Survival in Ovarian Cancer","authors":"H. Semiz","doi":"10.14744/ejmi.2023.76099","DOIUrl":"https://doi.org/10.14744/ejmi.2023.76099","url":null,"abstract":"cor-Objectives: Due to limited data in the literature, we aimed to determine the relationship between the development of chemotherapy-induced neutropenia and survival in patients with ovarian cancer who underwent frontline cytoreductive surgery and received adjuvant chemotherapy","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127772635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2023.58954
F. Ferhatoğlu
Objectives: The adrenal gland is one of the most common metastatic sites in lung cancer. The anatomical localization and symmetrical nature of the glands provided the concepts of laterality and resectability of adrenal gland metastasis (AGM) in lung cancer. In this trial, we aimed to investigate the clinical features and prognosis specific to ipsilateral AGM and compare them with contralateral AGM in lung cancer patients from a single tertiary center. Methods: Data of 135 lung cancer patients with AGM were retrospectively collected. The patients were divided into two groups as ipsilateral AGM and contralateral AGM. Clinicopathological features and survival outcomes were compared. Results: 57 lung cancer patients (42.2%) had ipsilateral AGM. Isolated AGM was significantly more prevalent in patients with ipsilateral AGM than those with contralateral AGM (29.4% vs. 14.1%; p=0.026). Patients with ipsilateral AGM have a survival advantage compared to contralateral AGM (The median OS: 11.6 months vs. 7.8 months; p=0.008). In multi-variate analysis, ipsilateral AGM had a favorable independent prognostic factor (Hazard Ratio=0.61; %95Confidential interval: 0.40-0.92; p=0.018). Conclusion: In patients with lung cancer, ipsilateral AGM is more likely to be isolated and is associated with a better prognosis compared to contralateral AGM.
{"title":"Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study","authors":"F. Ferhatoğlu","doi":"10.14744/ejmi.2023.58954","DOIUrl":"https://doi.org/10.14744/ejmi.2023.58954","url":null,"abstract":"Objectives: The adrenal gland is one of the most common metastatic sites in lung cancer. The anatomical localization and symmetrical nature of the glands provided the concepts of laterality and resectability of adrenal gland metastasis (AGM) in lung cancer. In this trial, we aimed to investigate the clinical features and prognosis specific to ipsilateral AGM and compare them with contralateral AGM in lung cancer patients from a single tertiary center. Methods: Data of 135 lung cancer patients with AGM were retrospectively collected. The patients were divided into two groups as ipsilateral AGM and contralateral AGM. Clinicopathological features and survival outcomes were compared. Results: 57 lung cancer patients (42.2%) had ipsilateral AGM. Isolated AGM was significantly more prevalent in patients with ipsilateral AGM than those with contralateral AGM (29.4% vs. 14.1%; p=0.026). Patients with ipsilateral AGM have a survival advantage compared to contralateral AGM (The median OS: 11.6 months vs. 7.8 months; p=0.008). In multi-variate analysis, ipsilateral AGM had a favorable independent prognostic factor (Hazard Ratio=0.61; %95Confidential interval: 0.40-0.92; p=0.018). Conclusion: In patients with lung cancer, ipsilateral AGM is more likely to be isolated and is associated with a better prognosis compared to contralateral AGM.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126231415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2021.27607
Burcu Yapar Taskoylu
COVID-19 since erupted in Wuhan city, China at the end of December 2019, has been exercising great influence all over the world and in Turkey as well. Cancer patients under treatment constitute a risk group for the infection. The management of specific side effects related to targeted treatment agents and immunotherapies have become a vital issue in this period. As COVİD-19 infecition is a novel clinical picture the avaible data on the possible effects caused by the virus on the clinical course in cancer patients is limited.[1] Cancer patients due to their systemic immunosuppressive state caused by both the cancer itself and the treatment are more prone to develop infections than other patients.[2] Given the necessity to continue cancer treatment and the possibility of high mortality due to COVID-19 in immunocompromised hosts managing treatment for cancer has become more difficult during the Burcu Yapar Taskoylu,1 Tugba Sari,2 Atike Gokcen Demiray,1 Serkan Degirmencioglu,1 Gamze Gokoz Dogu,1 Arzu Yaren,1 Ahmet Ergin,3 Esin Avci,4 Canan Karan,1 Burcin Cakan Demirel,1 Tolga Dogan,1 Melek Ozdemir1
{"title":"Evaluation of Clinical, Laboratory and Treatment Findings of Oncology Patients Diagnosed with COVID-19 Infection","authors":"Burcu Yapar Taskoylu","doi":"10.14744/ejmi.2021.27607","DOIUrl":"https://doi.org/10.14744/ejmi.2021.27607","url":null,"abstract":"COVID-19 since erupted in Wuhan city, China at the end of December 2019, has been exercising great influence all over the world and in Turkey as well. Cancer patients under treatment constitute a risk group for the infection. The management of specific side effects related to targeted treatment agents and immunotherapies have become a vital issue in this period. As COVİD-19 infecition is a novel clinical picture the avaible data on the possible effects caused by the virus on the clinical course in cancer patients is limited.[1] Cancer patients due to their systemic immunosuppressive state caused by both the cancer itself and the treatment are more prone to develop infections than other patients.[2] Given the necessity to continue cancer treatment and the possibility of high mortality due to COVID-19 in immunocompromised hosts managing treatment for cancer has become more difficult during the Burcu Yapar Taskoylu,1 Tugba Sari,2 Atike Gokcen Demiray,1 Serkan Degirmencioglu,1 Gamze Gokoz Dogu,1 Arzu Yaren,1 Ahmet Ergin,3 Esin Avci,4 Canan Karan,1 Burcin Cakan Demirel,1 Tolga Dogan,1 Melek Ozdemir1","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125488118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2021.14888
Ozden Yildirim Akan
Objectives: The Covid-19 has been spreading rapidly worldwide. We investigated the effects of some laboratory parameters of patients diagnosed with Covid-19 on admission to the intensive care unit and mortality rate. We aim to be a reference to other countries with demonstrating the effect of laboratory parameters to prognosis and mortality as a center from Turkey. Methods: One hundred sixty patients diagnosed with Covid-19 that confirmed with PCR test included the study. The neutrophil/lymphocyte, neutrophil/monocyte neutrophil/platelet ratios, and C-reactive protein levels were evaluated. Patients were divided into 2 groups;who admitted to intensive care unit and who were treated in Covid-19 inpatient clinic without intensive care need. The groups were statistically compared. Mortality rates were examined to determine a cut-off value for each parameters. Results: These parameters and C-reactive protein levels of the Covid-19 patients were found to be statistically significant in both admission to the intensive care and mortality. The upper limits of these determined cut-off values are predicted to be critical for admission to intensive care. The cut-off values for NLR, NMR, NPR and CRP for mortality rate were 9.5, 3.7, 0.022, 79.2. Among these parameters, it was seen that the best determinant for mortality rate was CRP (cut-off=79.2). Conclusion: It was observed that NLR, NMR, NPR and CRP values were significant in determining the need for intensive care unit and mortality rate in patients diagnosed with Covid-19.
{"title":"Effects of Neutrophil/Monocyte, Neutrophil/Lymphocyte, Neutrophil/Platelet Ratios and C-Reactive Protein levels on the mortality and intensive care need of the patients with Covid-19","authors":"Ozden Yildirim Akan","doi":"10.14744/ejmi.2021.14888","DOIUrl":"https://doi.org/10.14744/ejmi.2021.14888","url":null,"abstract":"Objectives: The Covid-19 has been spreading rapidly worldwide. We investigated the effects of some laboratory parameters of patients diagnosed with Covid-19 on admission to the intensive care unit and mortality rate. We aim to be a reference to other countries with demonstrating the effect of laboratory parameters to prognosis and mortality as a center from Turkey. Methods: One hundred sixty patients diagnosed with Covid-19 that confirmed with PCR test included the study. The neutrophil/lymphocyte, neutrophil/monocyte neutrophil/platelet ratios, and C-reactive protein levels were evaluated. Patients were divided into 2 groups;who admitted to intensive care unit and who were treated in Covid-19 inpatient clinic without intensive care need. The groups were statistically compared. Mortality rates were examined to determine a cut-off value for each parameters. Results: These parameters and C-reactive protein levels of the Covid-19 patients were found to be statistically significant in both admission to the intensive care and mortality. The upper limits of these determined cut-off values are predicted to be critical for admission to intensive care. The cut-off values for NLR, NMR, NPR and CRP for mortality rate were 9.5, 3.7, 0.022, 79.2. Among these parameters, it was seen that the best determinant for mortality rate was CRP (cut-off=79.2). Conclusion: It was observed that NLR, NMR, NPR and CRP values were significant in determining the need for intensive care unit and mortality rate in patients diagnosed with Covid-19.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121939329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.79013
Z. Kalkan
Objectives: The prognosis of metastatic malignant melanoma is poor. In this study, we aim to evaluate the response rates, PFS and OS times obtained with Nivolumab, Ipilimumab and Dabrafenib plus Trametinib in the treatment of advanced malignant melanoma, as well as the side effect profiles of these three agents. Methods: This study included 58 patients diagnosed with advanced malignant melanoma who received Nivolumab, Ipilimumab or Dabrafenib plus Trametinib therapy between January 2010 - March 2021 and had follow-up at our clin-ic. Response rates, survival times and side effects associated with each of the three treatment arms were evaluated. Nivolumab, Ipilimumab and Dabrafenib plus Trametinib were compared with regard to effectiveness and tolerability. Results: The Nivolumab, Ipilimumab and Dabrafenib plus Trametinib treatment arms, included 34 (58.6%), 13 (22.4%) and 11 (19%) patients, respectively. The comparison of Nivolumab, Ipilimumab and Dabrafenib plus Trametinib yielded, respectively; ORR (53%, 38.5%, 72.8%), mPFS (7 months, 3 months, 9 months) (p=0.57), mOS (12 months, 16 months, 15 months) (p=0.85). Conclusion: In this study that we conducted with real life data, we confirmed that Nivolumab, Ipilimumab and Dabrafenib plus Trametinib have different effectiveness adn manageable side effect profiles in the treatment of advanced malignant melanoma. Abstract
{"title":"Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma","authors":"Z. Kalkan","doi":"10.14744/ejmi.2022.79013","DOIUrl":"https://doi.org/10.14744/ejmi.2022.79013","url":null,"abstract":"Objectives: The prognosis of metastatic malignant melanoma is poor. In this study, we aim to evaluate the response rates, PFS and OS times obtained with Nivolumab, Ipilimumab and Dabrafenib plus Trametinib in the treatment of advanced malignant melanoma, as well as the side effect profiles of these three agents. Methods: This study included 58 patients diagnosed with advanced malignant melanoma who received Nivolumab, Ipilimumab or Dabrafenib plus Trametinib therapy between January 2010 - March 2021 and had follow-up at our clin-ic. Response rates, survival times and side effects associated with each of the three treatment arms were evaluated. Nivolumab, Ipilimumab and Dabrafenib plus Trametinib were compared with regard to effectiveness and tolerability. Results: The Nivolumab, Ipilimumab and Dabrafenib plus Trametinib treatment arms, included 34 (58.6%), 13 (22.4%) and 11 (19%) patients, respectively. The comparison of Nivolumab, Ipilimumab and Dabrafenib plus Trametinib yielded, respectively; ORR (53%, 38.5%, 72.8%), mPFS (7 months, 3 months, 9 months) (p=0.57), mOS (12 months, 16 months, 15 months) (p=0.85). Conclusion: In this study that we conducted with real life data, we confirmed that Nivolumab, Ipilimumab and Dabrafenib plus Trametinib have different effectiveness adn manageable side effect profiles in the treatment of advanced malignant melanoma. Abstract","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132081952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Effects of the Covid-19 Pandemic on the Number of Publications in Oncology Journals: A Big Data Analysis","authors":"Yakkup Iriagac","doi":"10.14744/ejmi.2021.99063","DOIUrl":"https://doi.org/10.14744/ejmi.2021.99063","url":null,"abstract":"DOI: 10.14744/ejmi.2021.99063 EJMI 2021;5(3):360–373","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"437 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132863198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Could Pretreatment Neutrophil/Lymphosit Ratio and Derived Neutrophil/Lymphosit Ratio Predict Overall Survival of Patients With Extensive Stage Small Cell Lung Cancer?","authors":"A. Bahceci","doi":"10.14744/ejmi.2022.53326","DOIUrl":"https://doi.org/10.14744/ejmi.2022.53326","url":null,"abstract":"DOI: 10.14744/ejmi.2022.53326 EJMI 2022;6(1):33–37","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"48 ","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131692830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2023.28845
Tuğba Başoğlu
Objectives: Our aim is to investigate the prognostic value and effect on chemotherapy toxicity of pre-treatment sarcopenia determined with positron emission tomography/computerized tomography(PET/CT) in patients with ampullary carcinoma. Methods: Characteristics of patients retrieved retrospectively. Skeletal muscle area(SMA) measurement of the muscle at L3 vertebra level was evaluated for each patient from their PET/CT scan taken at the time of diagnosis. The sex-spe-cific cut-off levels for determining sarcopenia were <38.5 cm2/m2 for females and <52.4 cm2/m2 for males. Association between oncological and radiological data was analyzed. Results: A total of 90 patients included in the study. Median age at diagnosis was 62(range: 44-77). Half of the patients were sarcopenic. Pre-treatment sarcopenia was determined as an independent variable predicting survival for both disease-free-survival(DFS) and overall survival(OS). Sarcopenic patients had statistically significant shorter OS(67.2 months for non-sarcopenic patients vs 53.2 months for sarcopenic patients, 95%CI:63.6-70.9, p<0.001), and a trend for shorter DFS(48 months for non-sarcopenic patients vs 36.8 months for sarcopenic patients, 95%CI:20.3-53.4, p=0.95) was also determined. On the other hand, chemotherapy related toxicity has also seen more in sarcopenic patients. Conclusion: Detecting the presence of pre-treatment sarcopenia may enable clinicians to predict the patient group with low survival and high probability of treatment toxicity. In order to protect this group of patients from toxicity, pre-treatment sarcopenia measurement should be applied in routine practice and should guide treatment plan. Abstract Cite This Article: Basoglu T, Ozguven S, Engur CO, Akagunduz F, Demircan NC, Arikan R, et al. Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. EJMI 2023;7(1):32–41.
{"title":"Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma","authors":"Tuğba Başoğlu","doi":"10.14744/ejmi.2023.28845","DOIUrl":"https://doi.org/10.14744/ejmi.2023.28845","url":null,"abstract":"Objectives: Our aim is to investigate the prognostic value and effect on chemotherapy toxicity of pre-treatment sarcopenia determined with positron emission tomography/computerized tomography(PET/CT) in patients with ampullary carcinoma. Methods: Characteristics of patients retrieved retrospectively. Skeletal muscle area(SMA) measurement of the muscle at L3 vertebra level was evaluated for each patient from their PET/CT scan taken at the time of diagnosis. The sex-spe-cific cut-off levels for determining sarcopenia were <38.5 cm2/m2 for females and <52.4 cm2/m2 for males. Association between oncological and radiological data was analyzed. Results: A total of 90 patients included in the study. Median age at diagnosis was 62(range: 44-77). Half of the patients were sarcopenic. Pre-treatment sarcopenia was determined as an independent variable predicting survival for both disease-free-survival(DFS) and overall survival(OS). Sarcopenic patients had statistically significant shorter OS(67.2 months for non-sarcopenic patients vs 53.2 months for sarcopenic patients, 95%CI:63.6-70.9, p<0.001), and a trend for shorter DFS(48 months for non-sarcopenic patients vs 36.8 months for sarcopenic patients, 95%CI:20.3-53.4, p=0.95) was also determined. On the other hand, chemotherapy related toxicity has also seen more in sarcopenic patients. Conclusion: Detecting the presence of pre-treatment sarcopenia may enable clinicians to predict the patient group with low survival and high probability of treatment toxicity. In order to protect this group of patients from toxicity, pre-treatment sarcopenia measurement should be applied in routine practice and should guide treatment plan. Abstract Cite This Article: Basoglu T, Ozguven S, Engur CO, Akagunduz F, Demircan NC, Arikan R, et al. Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. EJMI 2023;7(1):32–41.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133773585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.90000
T. Koseci
Objectives: Trastuzumab emtansine(T-DM1) is more effective in some patients. However, predictive factors are not clear for T-DM1 efficacy. We attempt to explore prognostic importance of albumin to alkaline phosphotase ratio (AAPR) and prognostic nutritional index (PNI) importance in patients who used T-DM1. Methods: The present retrospective study included the sixty-one human epidermal growh factor-2 (HER-2) positive metastatic breast cancer patients who used T-DM1. The median values were used to analyze AAPR and PNI threshold. PNI and AAPR were measured at baseline and after one cycle. Survival analysis was performed by using Kaplan-Meier method and compared with log rank test. Univariate and multivariate analysis were performed to determine independent prognostic predictor of progression-free survival (PFS) and overall survival (OS). Results: The optimal cutoff value for AAPR and PNI were 0.41 and 45.0, respectively. OS and PFS were obviously inferior in patients with AAPR<0.41 compared to patients with AAPR≥0.41 according to Kaplan-Meier curve (OS: p=0.028, PFS: p=0.047). Patients with PNI <45 prominently demonstrated poor OS and PFS than those with PNI≥45 according to Kaplan-Meier curve (OS: p=0.033, PFS: p=0.071). Conclusion: Pretreatment PNI is reliable prognostic indicators in patients with mBC treated by T-DM1. Abstract
{"title":"Importance of Prognostic Nutritional Index in Patients with Metastatic Breast Cancer Treated with Trastuzumab Emtansine","authors":"T. Koseci","doi":"10.14744/ejmi.2022.90000","DOIUrl":"https://doi.org/10.14744/ejmi.2022.90000","url":null,"abstract":"Objectives: Trastuzumab emtansine(T-DM1) is more effective in some patients. However, predictive factors are not clear for T-DM1 efficacy. We attempt to explore prognostic importance of albumin to alkaline phosphotase ratio (AAPR) and prognostic nutritional index (PNI) importance in patients who used T-DM1. Methods: The present retrospective study included the sixty-one human epidermal growh factor-2 (HER-2) positive metastatic breast cancer patients who used T-DM1. The median values were used to analyze AAPR and PNI threshold. PNI and AAPR were measured at baseline and after one cycle. Survival analysis was performed by using Kaplan-Meier method and compared with log rank test. Univariate and multivariate analysis were performed to determine independent prognostic predictor of progression-free survival (PFS) and overall survival (OS). Results: The optimal cutoff value for AAPR and PNI were 0.41 and 45.0, respectively. OS and PFS were obviously inferior in patients with AAPR<0.41 compared to patients with AAPR≥0.41 according to Kaplan-Meier curve (OS: p=0.028, PFS: p=0.047). Patients with PNI <45 prominently demonstrated poor OS and PFS than those with PNI≥45 according to Kaplan-Meier curve (OS: p=0.033, PFS: p=0.071). Conclusion: Pretreatment PNI is reliable prognostic indicators in patients with mBC treated by T-DM1. Abstract","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115458717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Some Biochemical Responses in Cigarette Addicts who Receive Royal Jelly Supplement","authors":"A. Taşdoğan, Z. Pancar","doi":"10.14744/ejmi.2019.52853","DOIUrl":"https://doi.org/10.14744/ejmi.2019.52853","url":null,"abstract":"DOI: 10.14744/ejmi.2020.28402 EJMI 2020;4(2):204–208","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124407990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：